German biotech InflaRx raises $100M in IPO
InflaRx, a German biopharma developing drugs for rare diseases, has raised $100 million in the industry’s third IPO this month.
The company sold 6.7 million shares at $15, the midpoint of their $14 to $16 range. Insiders snapped up 40% — or $40 million — of the deal.
It’s more than the company originally expected to raise. InflaRx planned on raising about $86 million, according to a statement filed with the SEC back in October.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
